T. Arledge

644 total citations
12 papers, 510 citations indexed

About

T. Arledge is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, T. Arledge has authored 12 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 8 papers in Immunology and 2 papers in Hematology. Recurrent topics in T. Arledge's work include Spondyloarthritis Studies and Treatments (8 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). T. Arledge is often cited by papers focused on Spondyloarthritis Studies and Treatments (8 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Psoriasis: Treatment and Pathogenesis (6 papers). T. Arledge collaborates with scholars based in United States, Belgium and Germany. T. Arledge's co-authors include Danuta Kielar, C. Stach, Bengt Hoepken, Philip J. Mease, Roy Fleischmann, Franz Woltering, Atul Deodhar, J. Wollenhaupt, Désirée van der Heijde and Majed Khraishi and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

T. Arledge

12 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Arledge United States	6	378	350	217	59	51	12	510
John Brockbank United Kingdom	8	471 1.2×	406 1.2×	268 1.2×	16 0.3×	23 0.5×	10	551
Leonieke van Mens Netherlands	12	433 1.1×	328 0.9×	193 0.9×	15 0.3×	8 0.2×	29	522
L. Linares Spain	11	353 0.9×	230 0.7×	117 0.5×	28 0.5×	13 0.3×	26	512
S. Mudivarthy Canada	3	578 1.5×	489 1.4×	363 1.7×	17 0.3×	7 0.1×	4	705
Joke de Boer Netherlands	13	218 0.6×	45 0.1×	168 0.8×	28 0.5×	45 0.9×	28	550
J. B. Kuemmerle‐Deschner Germany	7	83 0.2×	140 0.4×	138 0.6×	12 0.2×	18 0.4×	25	350
S. Biester Germany	8	166 0.4×	78 0.2×	161 0.7×	15 0.3×	39 0.8×	15	543
Jacqueline E Paramarta Netherlands	10	323 0.9×	256 0.7×	147 0.7×	10 0.2×	6 0.1×	12	424
Roseneide Aparecida Conde Brazil	7	239 0.6×	111 0.3×	59 0.3×	9 0.2×	34 0.7×	11	273
Guo Xia China	10	254 0.7×	241 0.7×	101 0.5×	9 0.2×	6 0.1×	12	375

Countries citing papers authored by T. Arledge

Since Specialization

Citations

This map shows the geographic impact of T. Arledge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Arledge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Arledge more than expected).

Fields of papers citing papers by T. Arledge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Arledge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Arledge. The network helps show where T. Arledge may publish in the future.

Co-authorship network of co-authors of T. Arledge

This figure shows the co-authorship network connecting the top 25 collaborators of T. Arledge. A scholar is included among the top collaborators of T. Arledge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Arledge. T. Arledge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Walsh, Jessica A., T. Arledge, T. Nurminen, Luke Peterson, & J. Stark. (2018). PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol. The Journal of Rheumatology. 45(7). 922–928. 5 indexed citations

Khraishi, Majed, Bengt Hoepken, O. Davies, et al.. (2015). THU0427 Sustained Improvements in Skin Outcomes Following Certolizumab Pegol Treatment of Psoriatic Arthritis Patients with Prior Anti-TNF Exposure or Severe Skin Involvement at Baseline. Annals of the Rheumatic Diseases. 74. 353–354. 1 indexed citations

Sieper, J., Martín Rudwaleit, Désirée van der Heijde, et al.. (2014). LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL. Clinical and Experimental Rheumatology. 32(5). 785–786. 1 indexed citations

Mease, Philip, R Fleischmann, J. Wollenhaupt, et al.. (2013). EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY. Lara D. Veeken. 52(10). 162–163. 4 indexed citations

Heijde, D. van der, Roy Fleischmann, J. Wollenhaupt, et al.. (2013). Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Annals of the Rheumatic Diseases. 73(1). 233–237. 60 indexed citations

Mease, Philip J., Roy Fleischmann, Atul Deodhar, et al.. (2013). Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Annals of the Rheumatic Diseases. 73(1). 48–55. 360 indexed citations

Landewé, Robert, Martín Rudwaleit, Désirée van der Heijde, et al.. (2013). OP0106 Effect of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24-Week Results of Rapid-Axspa Study. Annals of the Rheumatic Diseases. 72. A86–A87. 4 indexed citations

Mease, Philip J., Roy Fleischmann, J. Wollenhaupt, et al.. (2013). SAT0298 Effect of Certolizumab Pegol on Signs and Symptoms in Patients with Psoriatic Arthritis from the Rapid-PSA Study: Impact of Baseline Skin Involvement and Prior Anti-TNF Therapy. Annals of the Rheumatic Diseases. 72. A684–A685. 3 indexed citations

Landewé, Robert, Martín Rudwaleit, Désirée van der Heijde, et al.. (2012). Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study. Data Archiving and Networked Services (DANS). 64(10). 10 indexed citations

10.

Mease, Philip J., Roy Fleischmann, Ajita Deodhar, et al.. (2012). LB0001 Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (rapid-PSA). Annals of the Rheumatic Diseases. 71. 150–151. 5 indexed citations

11.

Weinstein, Steven F., et al.. (1998). Efficacy of Salmeterol Xinafoate Powder in Children with Chronic Persistent Asthma. Annals of Allergy Asthma & Immunology. 81(1). 51–58. 41 indexed citations

12.

Arledge, T., Roger F. Liddle, E. Ståhl, & Thomas H. Rossing. (1996). Salmeterol does not cause tolerance during long-term asthma therapy. Journal of Allergy and Clinical Immunology. 98(6). 1116–1119. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact